日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Directing the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells

引导无血清、体外扩增的Vγ9Vδ2 T细胞的迁移

Kiran K Parwani ,Gianna M Branella ,Rebecca E Burnham ,Andre J Burnham ,Austre Y Schiaffino Bustamante ,Elisabetta Manuela Foppiani ,Kristopher A Knight ,Brian G Petrich ,Edwin M Horwitz ,Christopher B Doering ,H Trent Spencer

Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction

通过祖先序列重建鉴定活性增强的凝血因子 IX 变体

Kristopher A Knight, Christopher W Coyle, Caelan E Radford, Ernest T Parker, Andrew Fedanov, Jordan M Shields, Fania Szlam, Anatolii Purchel, Michelle Chen, Gabriela Denning, Roman M Sniecinski, Pete Lollar, H Trent Spencer, Eric A Gaucher, Christopher B Doering

Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII

非基因毒性调节促进利用生物工程因子 VIII 进行血友病 A 的造血干细胞基因治疗

Athena L Russell, Chengyu Prince, Taran S Lundgren, Kristopher A Knight, Gabriela Denning, Jordan S Alexander, Jaquelyn T Zoine, H Trent Spencer, Shanmuganathan Chandrakasan, Christopher B Doering

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

体外扩增的患者来源的 γδT 细胞免疫疗法增强小鼠模型中的神经母细胞瘤肿瘤消退

Jaquelyn T Zoine, Kristopher A Knight, Lauren C Fleischer, Kathryn S Sutton, Kelly C Goldsmith, Christopher B Doering, H Trent Spencer

Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines

在 NK 和 CRISPR 编辑的 T 细胞系中使用两种结构不同的抗 CD5 抗原结合域开发针对 T 细胞恶性肿瘤的嵌合抗原受体

Sunil S Raikar, Lauren C Fleischer, Robert Moot, Andrew Fedanov, Na Yoon Paik, Kristopher A Knight, Christopher B Doering, H Trent Spencer